An interventional study of Pain Disengagement Training in Chronic Musculoskeletal Pain, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies in Musculoskeletal Pain with a site in United States — 29 open to participants now, 35 under way, 1 of them phase 3. Musculoskeletal Pain · United States.
Among the 155 studies in Musculoskeletal Pain with a site in United States, this one is the 125th largest by enrollment of the 136 interventional ones that give a count, is one of 11 that started in 2025, is one of 114 with no phase, and was the 131st registered.
518 studies on the registry are indexed under Musculoskeletal Pain; 127 are open to participants now.
Browse Musculoskeletal Pain studies →29 of the 155 studies in Musculoskeletal Pain with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
Margaret L Gourlay, MD, MPH · Sites in United States
Ages 50–64
Stanford University · Sites in United States
Ages 18+
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
University of Utah · Sites in United States
Ages 40–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Musculoskeletal Pain studies recruiting now, 30 (45%) set no upper age limit and 30 (45%) stop at 75 or younger; 8 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 3 · Phase 4 6
First in 2002; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 69 across 373 interventional studies indexed under Musculoskeletal Pain.
Median enrollment 60 across the 136 interventional studies, 195 across the 19 observational. Of the 110 that completed or were terminated, 41 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 155 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 5 studies filed under Musculoskeletal Pain — fewer than ten, so there is no comparison to draw.
12 of the studies in Musculoskeletal Pain with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02979574Memorial Sloan Kettering Cancer CenterPEACE: Comparing Chronic Pain Treatment Options | 2026-11 |
| NCT06867757Stanford UniversityTargeted Realtime Assessment of Chronic Pain in Youth | 2026-11 |
| NCT07393503State University of New York at BuffaloMusculoskeletal Outcomes Using Tylenol/Ibuprofen vs. Oral Steroids in New Injuries | 2027-01 |
| NCT06886906Indiana UniversityExploring the Acute and Dynamic Relationships Between Movement and Pain in Older Adults With Musculoskeletal Pain | 2027-01-01 |
| NCT06119698Massachusetts General HospitalImproving Health for Older Adults With Pain Through Engagement | 2027-04-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 155 studies in Musculoskeletal Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators aim to conduct an open pilot trial to determine the initial feasibility of a self-directed writing-based intervention in individuals with chronic musculoskeletal pain and elevated pain catastrophizing. The investigators will assess the feasibility of recruitment, acceptability of the treatment, credibility and participant satisfaction, treatment adherence, and feasibility of assessments following pre-specified benchmarks.
Mind-body interventions are some of the most effective treatments for chronic pain, yet due to lack of resources, many are inaccessible to the patients who need them. The investigators seek to fill this gap by developing and testing Pain Disengagement Training (PDT) for the treatment of chronic pain catastrophizing, a key risk factor for pain interference. The investigators will administer the PDT treatment in a small number (approximately 10) of participants to evaluate initial benchmarks (the feasibility of recruitment, acceptability of the treatment, credibility and participant satisfaction, treatment adherence, and feasibility of assessments) and to assess participants' experience with the intervention using qualitative exit interviews. Results will inform the refinement of the intervention for a future larger trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention involves approximately 8 sessions. The first session will involve a psychoeducation component describing the association between negative emotions and pain and the rationale for the intervention strategies. The intervention sessions will consist of approximately 30 minutes of writing alternating between imaginal exposure writing and positive writing periods alternating back and forth (e.g., 3-5 minutes of imaginal exposure writing followed by 3-5 minutes of positive writing before returning to imaginal exposure writing, etc.). Exposure writing will involve writing about a pain-related catastrophic worry repeatedly until it becomes less anxiety-provoking. The positive writing topics will change with each prompt and will be structured by session theme (e.g., values/goals, meaningful activities). They will also complete between session practice by setting aside a time for worrying and then completing a meaningful activity.
Behavioral: Pain Disengagement Training
The intervention involves approximately 8 sessions. The first session will involve a psychoeducation component describing the association between negative emotions and pain and the rationale for the intervention strategies. The intervention sessions will consist of approximately 30 minutes of writing alternating between imaginal exposure writing and positive writing periods alternating back and forth (e.g., 3-5 minutes of imaginal exposure writing followed by 3-5 minutes of positive writing before returning to imaginal exposure writing, etc.). Exposure writing will involve writing about a pain-related catastrophic worry repeatedly until it becomes less anxiety-provoking. The positive writing topics will change with each prompt and will be structured by session theme (e.g., values/goals, meaningful activities). They will also complete between session practice by setting aside a time for worrying and then completing a meaningful activity.
Feasibility of recruitment
\>70% participants approached agree to participate in the intervention
Time frame: Baseline, post-test (6 weeks)
Acceptability of treatment
\>70% of participants attend at least 6 out of 8 sessions
Time frame: Baseline, post-test (6 weeks)
Credibility and Expectancy Questionnaire
Measures perception that the treatment is credible and will offer improvements. Credibility (4 items) is rated from 1-9 with higher scores indicating more credibility. Expectancy is rated from 0-10 with higher scores indicating greater expectancy of improvement.
Time frame: Baseline
Client Satisfaction Questionnaire
Measure of client satisfaction with a program or intervention. 8-item scale measured from 1 to 4 with greater scores indicating greater satisfaction.
Time frame: Post-test (6 weeks)
Adherence to intervention
Percent of writing sections demonstrate correct themes (e.g., anxiety words in imaginal exposure writing)
Time frame: Mid-intervention
Feasibility of assessments
\>70% of participants have no measures fully missing
Time frame: Baseline, post-test (6 weeks)
Numerical Rating Scale
Rating of pain intensity on a 0-10 1-item scale with greater scores indicating greater pain intensity
Time frame: Baseline, post-test (6 weeks)
Graded Chronic Pain Scale
Measure of pain severity. 3-item scale rated from 0 to 10 with greater scores indicating greater pain severity and interference
Time frame: Baseline, post-test (6 weeks)
PROMIS Pain Interference scale
Assesses pain interference in the past 7 days in activities, work, chores, etc. 8-item scale (1 - not at all to 5 - very much) with greater scores indicating greater pain interference.
Time frame: Baseline, post-test (6 weeks)
Brief Pain Inventory
Assesses pain intensity (4 items) on a 0 to 10 scale with greater scores indicating worse pain intensity and interference.
Time frame: Baseline, post-test (6 weeks)
Patient Health Questionnaire - 9
Measure of depressive symptoms. 9-item scale rated from 0 to 3 with greater scores indicating greater depressive symptoms.
Time frame: Baseline, post-test (6 weeks)
PROMIS depression scale-8
Measure of depressive symptoms. 8-item scale rated from 1 to 5 with greater scores indicating greater depressive symptoms.
Time frame: Baseline, post-test (6 weeks)
Penn State Worry Questionnaire - abbreviated
8-item measure of worry rated from 1 to 5 with greater scores indicating greater worry.
Time frame: Baseline, post-test (6 weeks)
Pain Catastrophizing Scale
Assesses magnification, helplessness, and rumination in response to pain. 13-item scale rated 0 to 4 with greater scores indicating greater pain catastrophizing.
Time frame: Baseline, post-test (6 weeks)
Pain Anxiety Symptom Scale - Short Form (PASS-20)
Assesses fear and anxiety in response to pain. 20-item scale rated 0 to 5 with greater scores indicating greater pain anxiety.
Time frame: Baseline, post-test (6 weeks)
Worry Disengagement Questionnaire
Measures ability to shift attention from worry. 4-item scale rated from 0 to 10 with greater scores indicating greater ability to shift attention away from worry.
Time frame: Baseline, post-test (6 weeks)
Behavioral Activation for Depression Scale - Short Form
Assesses engagement in meaningful activities. 9-item measure rated from 0 to 6 with greater scores indicating greater activity engagement.
Time frame: Baseline, post-test (6 weeks)
Positive emotion rating scale
Assesses level of emotional intensity on a 4-item scale from 1 to 5 with greater scores indicating more positive emotionality.
Time frame: Mid-intervention
Contrast Avoidance Questionnaire-General Emotion and Worry subscales
Measures ability to sustain negative emotionality to protect against sudden shifts in emotion. 25-item scale rated from 1 to 5 with greater scores indicating greater avoidance of contrasting emotional states.
Time frame: Baseline, post-test (6 weeks)
PROMIS meaning and purpose scale short form 4a
4 item scale assessing meaning and fulfillment in life (1 to 5 rating scale)
Time frame: Baseline, post-test (6-weeks)
Self-Compassion Scale
12 item 1 to 5 scale measuring self-compassion
Time frame: Baseline, Post-test (6 weeks)
Plan to share: Yes — De-identified data will include feasibility assessments, intervention measures (i.e., peak emotion during writing periods) and pre and post intervention self-report questionnaires in the open pilot.
Supporting information: Statistical analysis plan, Analytic code
Time frame: Data from this study will be deposited into the repositories no later than the end of the funded project period. Data will be available indefinitely and will only be removed from the repository if requested by NIH or other relevant institution policy.
Access criteria: Data will be stored in the Vivli repository, an NIH-approved independent, generalist global data-sharing and analytics platform. Researchers will be able to access the data by request. Investigators will need to provide evidence of their institution's IRB approval for planned analyses of the data and upon the contingency that data only be used for research and secured by electronic safeguards. Further, this agreement will state that data will be destroyed once data analysis is complete.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Oct 2025 to primary completion in Oct 2026, 11 months.
Of 226 non-industry interventional studies with no phase under Musculoskeletal Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's 11 months is below that.
Counting every sponsor, half of 239 studies reached it within 12 months; a quarter within 5 and three quarters within 32.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2026 → Oct 2026 and completion Dec 2026 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →